InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,612.80
(
0.00%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.02
(
-1.02%
)
Bitcoin
62,201.13
(
-0.21%
)
Post# of 251748
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

willyw

Send PM Follow Ignore
Followers 14
Posts 733
Boards Moderated 0
Alias Born 12/09/2013

willyw

Re: DewDiligence post# 213684

Friday, 09/15/2017 8:56:06 PM

Friday, September 15, 2017 8:56:06 PM

Post# of 251748
No, I'm unaware of the tweet/tweep.
My source was a HCV forum.
A person who was denied Harvoni recently had their doctor contact them a few weeks ago with an offer to treat w/ Mavyret.
No one on the forum initially knew what Mavyret was (or was aware it was G/P).

Point is IF some higher priced Gilead treatments are still not treating some lower stage damaged groups, but Mavyet is, it would be positive for Abbvie/Enta. It may also foretell a higher market share for G/P.

Speculation (or hope) on my part.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up